The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Durability of Radiofrequency Ablation in Barrett's Esophagus With Dysplasia
Open accessAbstract
Background & Aims Radiofrequency ablation (RFA) can eradicate dysplasia and intestinal metaplasia in patients with dysplastic Barrett’s esophagus (BE), and reduce rates of esophageal adenocarcinoma. We assessed long-term rates of eradication, durability of neosquamous epithelium, disease progression, and safety of RFA in patients with dysplastic BE. Methods We performed a randomized trial of 127 subjects with dysplastic BE; after cross-over subjects were included 119 received RFA. Subjects were followed for a mean time of 3.05 years; the study was extended to 5 years for patients with eradication of intestinal metaplasia at 2 years. Outcomes included eradication of dysplasia or intestinal metaplasia after 2 and 3 years, durability of response, disease progression, and adverse events. Results After 2 years, 101/106 patients had complete eradication of all dysplasia (95%) and 99/106 had eradication of intestinal metaplasia (93%). After 2 years, among subjects with initial low-grade dysplasia, all dysplasia was eradicated in 51/52 (98%) and intestinal metaplasia was eradicated in 51/52 (98%); among subjects with initial high-grade dysplasia, all dysplasia was eradicated in 50/54 (93%) and intestinal metaplasia was eradicated in 48/54 (89%). After 3 years, dysplasia was eradicated in 55/56 of subjects (98%) and intestinal metaplasia was eradicated in 51/56 (91%). Kaplan-Meier analysis showed that dysplasia remained eradicated in >85% of patients and intestinal metaplasia in >75%, without maintenance RFA. Serious adverse events occurred in 4/119 subjects (3.4%); the rate of stricture was 7.6%. The rate of esophageal adenocarcinoma was 1/181 pt-yrs (0.55%/pt-yr); there was no cancer-related morbidity or mortality. The annual rate of any neoplastic progression was 1/73 pt-yrs (1.37%/pt-yr). Conclusion In subjects with dysplastic BE, RFA therapy has an acceptable safety profile, is durable, and is associated with a low rate of disease progression, for up to 3 years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Updated Guidelines 2008 for the Diagnosis, Surveillance and Therapy of Barrett's Esophagus
Wang, K. K., & Sampliner, R. E. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01835.x · Cited by 2,014
Self-citationRadiofrequency Ablation in Barrett's Esophagus with Dysplasia
Shaheen, N. J., Sharma, P., Overholt, B. F., Wolfsen, H. C., Sampliner, R. E., Wang, K. K., Galanko, J. A., Bronner, M. P., Goldblum, J. R., Bennett, A. E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808145 · Cited by 1,438
Self-citationLong-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture
Yang, Y.-X., Lewis, J. D., Epstein, S., & Metz, D. C. (2006) · JAMA · doi:10.1001/jama.296.24.2947 · Cited by 1,214
Reproducibility of the diagnosis of dysplasia in Barrett esophagus: A reaffirmation
Montgomery, E., Bronner, M. P., Goldblum, J. R., Greenson, J. K., Haber, M. M., Hart, J., Lamps, L. W., Lauwers, G. Y., Lazenby, A. J., Lewin, D. N., et al. (2001) · Human Pathology · doi:10.1053/hupa.2001.23510 · Cited by 823
Self-citationAcid-suppressive medication use and the risk for hospital-acquired pneumonia
Herzig, S. J. (2009) · JAMA · doi:10.1001/jama.2009.722 · Cited by 486
Pouw, R. E., Wirths, K., Eisendrath, P., Sondermeijer, C. M., Ten Kate, F. J., Fockens, P., Devière, J., Neuhaus, H., & Bergman, J. J. (2010) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.07.003 · Cited by 311
van Vilsteren, F. G. I., Pouw, R. E., Seewald, S., Alvarez Herrero, L., Sondermeijer, C. M. T., Visser, M., ten Kate, F. J. W., Yu Kim Teng, K. C., Soehendra, N., Rösch, T., et al. (2011) · Gut · doi:10.1136/gut.2010.229310 · Cited by 310
Proton-Pump Inhibitor Use and the Risk for Community-Acquired Pneumonia
Sarkar, M., Hennessy, S., & Yang, Y.-X. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-6-200809160-00005 · Cited by 301
Proton Pump Inhibitors and Risk for Recurrent Clostridium difficile Infection
Linsky, A. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.73 · Cited by 276
Corley, D. A., Kubo, A., Zhao, W., & Quesenberry, C. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.03.055 · Cited by 271
Cited by
Phoa, K. N., Pouw, R. E., Bisschops, R., Pech, O., Ragunath, K., Weusten, B. L. A. M., Schumacher, B., Rembacken, B., Meining, A., Messmann, H., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-309298 · Cited by 265
Metadata
- Authors
- Shaheen, N. J., Overholt, B. F., Sampliner, R. E., Wolfsen, H. C., Wang, K. K., Fleischer, D. E., Sharma, V. K., Eisen, G. M., Fennerty, M. B., Hunter, J. G., Bronner, M. P., Goldblum, J. R., Bennett, A. E., Mashimo, H., Rothstein, R. I., Gordon, S. R., Edmundowicz, S. A., Madanick, R. D., Peery, A. F., Muthusamy, V. R., Chang, K. J., Kimmey, M. B., Spechler, S. J., Siddiqui, A. A., Souza, R. F., Infantolino, A., Dumot, J. A., Falk, G. W., Galanko, J. A., Jobe, B. A., Hawes, R. H., Hoffman, B. J., Sharma, P., Chak, A., & Lightdale, C. J.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2011-08
- Volume
- 141
- Issue
- 2
- Pages
- 460-468
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2023770280
- Cited by
- 451
- References
- 14
- FWCI
- 53.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Durability of Radiofrequency Ablation in Barrett's Esophagus With Dysplasia. https://app.cochat.ai/papers/10.1053/j.gastro.2011.04.061
- The paper
- Shaheen, N. J., Overholt, B. F., Sampliner, R. E., Wolfsen, H. C., Wang, K. K., Fleischer, D. E., Sharma, V. K., Eisen, G. M., Fennerty, M. B., Hunter, J. G., Bronner, M. P., Goldblum, J. R., Bennett, A. E., Mashimo, H., Rothstein, R. I., Gordon, S. R., Edmundowicz, S. A., Madanick, R. D., Peery, A. F., . . . Lightdale, C. J. (2011). Durability of Radiofrequency Ablation in Barrett's Esophagus With Dysplasia. Gastroenterology. https://doi.org/10.1053/j.gastro.2011.04.061
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
